Dublin-based Keenova Therapeutics plc, a US-focused branded therapeutics company, announced on Friday the new and final updated data from its dedicated ventral curvature analysis of Peyronie's disease and XIAFLEX (collagenase clostridium histolyticum) at the American Urological Association (AUA) annual meeting, taking place from 15-18 May 2026.

Peyronie's disease is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.

According to the data, the clinical effectiveness and safety of XIAFLEX in patients with ventral curvature are consistent with outcomes observed in patients with other clinical presentations of Peyronie's disease.

XIAFLEX is indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

Jesse Mills, MD, Clinical Professor and Director of the Men's Clinic at UCLA, who is presenting the findings, said: "These new results are consistent with earlier studies and reinforce that XIAFLEX (collagenase clostridium histolyticum) is both effective and well tolerated for men with Peyronie's disease, including those with ventral curvature. Such outcomes are encouraging to clinicians and patients looking for nonsurgical treatment options, and they underscore the importance of continued research to further expand our understanding of Peyronie's disease and its treatment."